Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network Inc (NYSE: BFLY) pioneers accessible medical imaging solutions through its revolutionary Ultrasound-on-Chip™ technology. This dedicated news hub provides investors and healthcare professionals with essential updates on product innovations, financial developments, and strategic initiatives driving the future of point-of-care diagnostics.
Discover official press releases covering earnings announcements, regulatory milestones, and partnerships advancing AI-powered ultrasound technology. Our curated collection ensures timely access to verified information about BFLY's handheld imaging systems, educational programs, and market expansion efforts.
Key updates include product launch details, clinical validation studies, and executive leadership changes. Bookmark this page to monitor how Butterfly Network's cloud-connected devices and ScanLab™ training tools continue transforming medical imaging accessibility worldwide.
Butterfly Network (NYSE: BFLY) has announced the commencement of an underwritten public offering of Class A common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering. The net proceeds will be used to fund development and commercialization of new and existing products and services, as well as general corporate purposes.
TD Cowen, William Blair, and Lake Street Capital Markets are serving as bookrunners for the proposed offering, which is subject to market conditions. The offering is being made pursuant to a shelf registration statement on Form S-3 that became effective on August 22, 2023. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.
Butterfly Network (NYSE: BFLY) announced preliminary findings from a key study conducted with Rutgers Robert Wood Johnson Medical School, showing significant benefits of point-of-care ultrasound (POCUS) in hospital care. The study, presented at EchoEuro-Imaging Conference, focused on using cardiopulmonary POCUS for patients with unexplained shortness of breath.
The research compared hospital physicians using Butterfly iQ+ and iQ3 POCUS devices versus those not using POCUS. Key findings revealed substantial reductions in hospital length of stay (LOS): lower-acuity patients' LOS decreased from 6.7 to 5.6 days, while higher-acuity patients saw reduction from 39 to 16.7 days. Lower-acuity patients experienced up to 50% cost reduction. Daily lung ultrasound usage was identified as important for accelerating patient discharge.
The complete study is expected to be published in the first half of 2025.
Butterfly Network (NYSE: BFLY) announced preliminary, unaudited Q4 2024 revenue growth of approximately 35% year over year. The digital health company, known for its portable semiconductor-based ultrasound technology, reported exceeding expectations with accelerating growth throughout 2024.
The company plans to release audited fourth quarter and full year 2024 results in late February 2025, along with guidance for 2025. Management expressed confidence in maintaining strong top-line growth with continued fiscal discipline going forward. The company will present a business update at the 43rd J.P. Morgan Healthcare Conference on January 16, 2025.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place from January 13-16, 2025, at the Westin St. Francis in San Francisco.
President, CEO & Chairman Joseph DeVivo and EVP & CFO Heather Getz will present on January 16, 2025, at 7:30 AM PST. The presentation will be available via webcast on the Events & Presentations section of Butterfly's investor website and will remain accessible for replay until February 15, 2025.
Butterfly Network (NYSE: BFLY) has announced its participation in the upcoming virtual BTIG Digital Health Forum on November 25, 2024. The company's leadership will engage in two key presentations: a 9:00 AM ET Fireside Chat featuring CEO Joseph DeVivo and CFO Heather Getz discussing Butterfly's technology and strategy, and a 3:00 PM ET Panel Discussion where CMO Dr. John Martin will explore the impact of tools like Butterfly iQ3 on diagnostic and treatment approaches. One-on-one meetings with executives can be arranged through BTIG representatives.
Butterfly Network's iQ3™ handheld ultrasound device has won the Best Medical Technology Award at the 2024 Prix Galien USA Awards, often referred to as the 'Nobel Prize of Life Sciences.' The third-generation device, built on Butterfly's proprietary P4.3 semiconductor platform, represents a significant advancement in ultrasound technology with enhanced AI-powered features and digital image capture capabilities. The company's Ultrasound-on-Chip™ technology aims to make ultrasound imaging more affordable, sustainable, and scalable, leveraging Moore's Law to deliver increasingly powerful and cost-effective imaging tools.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld ultrasound technology, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024, in New York City. CEO Joseph DeVivo and CFO Heather Getz will conduct one-on-one meetings throughout the event. DeVivo will present a business overview at 11:00 am ET. The presentation will be available via webcast on the company's investor website until February 19, 2025.
Butterfly Network (NYSE: BFLY) reported strong Q3 2024 results with revenue of $20.6 million, up 33% year-over-year. The company reduced its net loss by 38% and net cash used in operations by 50%. Product revenue increased 55% to $13.5 million, while software and services revenue grew 5% to $7.0 million. The company launched iQ3 in Europe and expanded into Indonesia, the Netherlands, and Belgium. Based on strong performance, Butterfly raised its full-year 2024 guidance to $79-81 million in revenue and improved its adjusted EBITDA loss forecast to $42-40 million.
HeartFocus has launched its AI-powered Education app in partnership with Butterfly Network (NYSE: BFLY), designed to teach healthcare practitioners how to conduct clinical-grade heart scans using Butterfly's handheld ultrasound devices. The app helps users master 10 essential cardiac views through personalized, AI-powered learning pathways.
Compatible with Butterfly iQ3 and iQ+ probes on iOS iPads, the platform features advanced gamification for enhanced engagement. The app will be demonstrated at the ANCC MagPath 2024 conference and is currently available in the US and 22 other countries, with a -time offer of a free six-month license.
Butterfly Network, Inc. (NYSE: BFLY), a digital health company specializing in portable, semiconductor-based ultrasound technology, has announced its plans to report third quarter 2024 financial results on November 1, 2024, at 8:00 am ET. The company will host a conference call and webcast before market opening, featuring Joseph DeVivo, President, CEO, and Chairman of the Board, along with Heather Getz, EVP and CFO/COO.
The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website. Interested parties can also dial in to listen to the call. A replay of the call will be available until November 15, 2024, through various access methods provided in the announcement.
FAQ
What is the current stock price of Butterfly Network (BFLY)?
What is the market cap of Butterfly Network (BFLY)?
